Disc Medicine, Inc. (NASDAQ: IRON) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
69.18
+0.61+0.89%
News
Up 0.9% — Rosen Law Firm Encourages Disc Medicine, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - IRON (prnewswire.com).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 23.77% | Shs Outstand | 38.39M | Perf Week | -6.69% |
| Market Cap | 2.66B | Forward P/E | - | EPS next Y | -7.00 | Insider Trans | -2.72% | Shs Float | 27.61M | Perf Month | -13.74% |
| Enterprise Value | 2.00B | PEG | - | EPS next Q | -1.65 | Inst Own | - | Short Float | 26.68% | Perf Quarter | -1.47% |
| Income | -212.00M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 13.93 | Perf Half Y | 16.98% |
| Sales | 0.00 | P/B | 4.12 | EPS next Y | -9.04% | ROA | -33.45% | Short Interest | 7.37M | Perf YTD | -12.88% |
| Book/sh | 16.77 | P/C | 3.70 | EPS next 5Y | - | ROE | -37.17% | 52W High | 99.50 -30.47% | Perf Year | 14.65% |
| Cash/sh | 18.70 | P/FCF | - | EPS past 3/5Y | - | ROIC | -38.19% | 52W Low | 40.00 72.95% | Perf 3Y | 25.71% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 5.07% 3.80% | Perf 5Y | 36.45% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -66.16% | Oper. Margin | 0.00% | ATR (14) | 3.17 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 24.14 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 31.56 | Recom | 1.91 |
| Dividend Gr. 3/5Y | - | Current Ratio | 24.14 | EPS Q/Q | 2.53% | SMA20 | -9.85% | Beta | 0.90 | Target Price | 106.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | -10.10% | Rel Volume | 1.13 | Prev Close | 68.57 |
| Employees | 165 | LT Debt/Eq | 0.00 | Earnings | Nov 05 | SMA200 | -5.55% | Avg Volume | 548.86K | Price | 69.18 |
| IPO Date | Aug 12, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 10.08% - | Net Debt/EBITDA | 0.16 | Volume | 621,183 | Change | 0.89% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-16-26 | Reiterated | Wells Fargo | Overweight | $75 → $86 |
| Sep-10-26 | Reiterated | H.C. Wainwright | Buy | $70 → $120 |
| Sep-10-26 | Reiterated | Jefferies | $89 → $128 | |
| Aug-17-26 | Reiterated | Morgan Stanley | Overweight | $85 → $90 |
| May-14-26 | Reiterated | Morgan Stanley | Overweight | $75 → $80 |
| Feb-17-26 | Reiterated | Morgan Stanley | Overweight | $120 → $75 |
| Feb-17-26 | Reiterated | Stifel Nicolaus | $125 → $110 | |
| Feb-17-26 | Reiterated | Cantor Fitzgerald | Overweight | $125 |
| Feb-17-26 | Reiterated | Wedbush | Outperform | $110 → $88 |
| Feb-17-26 | Reiterated | BMO Capital | Outperform | $112 → $100 |
Latest News· Times ET
Sep-16-26
Sep-16-2606:16PM
05:10AM
Sep-15-26
Sep-15-2610:26AM
Sep-14-26
Sep-14-2611:01AM
Sep-11-26
Sep-11-2611:11AM
Sep-10-26
Sep-10-2607:08AM
Sep-09-26
Sep-09-2603:25PM
03:23PM
Sep-08-26
Sep-08-2606:37PM
Sep-07-26
Sep-07-2606:26PM
Sep-04-26
Sep-04-2601:26PM
Sep-02-26
Sep-02-2601:43PM
04:00AM
Disc Medicine to Participate in Upcoming Investor Conferencesglobenewswire.com
Sep-01-26
Sep-01-2612:11PM
Aug-31-26
Aug-31-2603:53PM
Company
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | |
| Gross Profit | 0 | 0 | 0 | — | — | — | |
| Selling, General and Administrative Excl. Other | 65 | 33 | 22 | — | — | — | |
| Research and Development | 171 | 97 | 69 | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | |
| Operating Income | -236 | -130 | -91 | — | — | — | |
| Interest Expense | 4 | 1 | 0 | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 28 | 21 | 15 | — | — | — | |
| Net Income Before Taxes | -212 | -109 | -76 | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | |
| Consolidated Net Income | -212 | -109 | -76 | — | — | — | |
| Net Income From Continuing Operations | -212 | -109 | -76 | — | — | — | |
| Net Income | -212 | -109 | -76 | — | — | — | |
| EPS (Recurring) | -6.01 | -3.96 | -3.42 | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -6.01 | -3.96 | -3.42 | — | — | — | |
| EPS (Diluted) | -6.01 | -3.96 | -3.42 | — | — | — | |
| EBITDA | -208 | -108 | -76 | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | |
| Shares Outstanding | 35 | 28 | 22 | — | — | — | |
| Market Capitalization | 2,779 | 1,775 | 1,271 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Quisel John D | Chief Executive Officer | Sep 15 '26 | Option Exercise | 1.01 | 36,000 | 36,360 | 262,064 | Sep 16 |
| Bitterman Kevin | Director | Sep 11 '26 | Option Exercise | 45.07 | 27,136 | 1,223,144 | 27,136 | Sep 15 |
| Bitterman Kevin | Director | Sep 11 '26 | Sale | 70.11 | 27,136 | 1,902,505 | 0 | Sep 15 |
| Bitterman Kevin | Director | Sep 04 '26 | Sale | 79.96 | 1,689 | 135,053 | 13,427 | Sep 09 |
| Bitterman Kevin | Director | Sep 03 '26 | Sale | 79.98 | 5,203 | 416,136 | 13,445 | Sep 03 |
| Bitterman Kevin | Director | Sep 02 '26 | Sale | 80.17 | 49,164 | 3,941,495 | 13,499 | Sep 03 |
| Bitterman Kevin | Director | Sep 01 '26 | Sale | 79.95 | 129 | 10,314 | 14,012 | Sep 03 |
| Yu Jonathan Yen-Wen | Chief Operating Officer | Aug 25 '26 | Sale | 83.12 | 8,796 | 731,092 | 54,324 | Aug 26 |
| Yu Jonathan Yen-Wen | Chief Operating Officer | Aug 25 '26 | Option Exercise | 13.50 | 8,796 | 118,746 | 63,120 | Aug 26 |
| Yu Jonathan Yen-Wen | Chief Operating Officer | Aug 24 '26 | Sale | 82.53 | 300 | 24,760 | 54,324 | Aug 26 |
| Yu Jonathan Yen-Wen | Chief Operating Officer | Aug 24 '26 | Option Exercise | 13.50 | 300 | 4,050 | 54,624 | Aug 26 |
| Quisel John D | Chief Executive Officer | Aug 17 '26 | Sale | 79.15 | 33,000 | 2,611,982 | 226,064 | Aug 18 |
| Quisel John D | Chief Executive Officer | Aug 17 '26 | Option Exercise | 13.50 | 33,000 | 445,500 | 259,064 | Aug 18 |
| Yu Jonathan Yen-Wen | Chief Operating Officer | Aug 12 '26 | Option Exercise | 13.50 | 804 | 10,854 | 55,128 | Aug 14 |
| Yu Jonathan Yen-Wen | Chief Operating Officer | Aug 12 '26 | Sale | 82.64 | 804 | 66,445 | 54,324 | Aug 14 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.